Cancer

A prospective, unblinded observational study was conducted to evaluate the efficacy of Psorinum 6X in treating people with stomach, gall bladder, pancreatic and liver cancers (Chatterjee, Biswas, Chatterjee, 2011). The participants' eligibility criteria included histopathology/cytopathology confirmation of malignancy, inoperable tumor, and no prior chemotherapy or radiation therapy. The primary outcome measures of the study were (i) to assess the radiological tumor response (ii) to find out how many participants survived at least 1 year, 2 years, 3 years, 4 years and finally 5 years after the beginning of the study considering each type of cancer.

Psorinum 6x was administered orally to all the participants up to 0.02 ml/Kg body weight as a single dose in empty stomach per day for 2 years along with allopathic and homeopathic supportive cares. 158 participants (42 of stomach, 40 of gall bladder, 44 of pancreatic, 32 of liver) were included in the final analysis of the study. Complete tumor response occurred in 28 (17.72%) cases and partial tumor response occurred in 56 (35.44%) cases.*[1]

Among the 39 participants (24.68%) who were diagnosed at stage-III, 13 (33.33%) had complete response and 16 (41.03%) had radiological partial response. Among the 112 (70.89%) participants who were diagnosed at stage-IV, 12 (10.71%) had radiological complete response and 38 (33.93%) had radiological partial response.  At least 60% participants of stage-III and at least 45% participants of stage-IV reported that the therapy was effective in reducing their cancer-related pain, cough, dysponea, nausea and vomiting, fatigue, constipation and improving appetite, and weakness.

Improvements were also observed in the lab investigations like Complete Blood Count (CBC), Liver Function Test (LFT), Kidney function test, AFP level, and CA 19.9.  Among the 158 participants, 98 (62.03%) were aged 65 years or more. Better outcomes were observed among the participants below 65 years of age than the participants who were over the age of 65.

Of special note are the results in treating patients with pancreatic cancer.  Of the 44 patients with pancreatic cancer, 33 (77%) survived at least one year, 28 (64%) survived two years, 21 (48%) survived four years, and 17 (39%) survived five years.  Because 95% of patients with pancreatic cancer die within the first year, these results are very significant.

The limitations of the above study is that it was not double-blind and placebo controlled.  Also, the participants received the drug Psorinum along with allopathic and homeopathic supportive treatments without trying conventional or any other investigational cancer treatments.  According to modern cancer treatment, it is unlikely that conventional supportive care can observe the above described highly significant results.

Of further interest is the fact that these researchers reference a half-dozen other trials testing Psorinum 6X that were all published in conventional oncology journals.

The researchers concluded that a double-blind randomized controlled clinical trial should be conducted for further scientific exploration of this alternative cancer treatment.

Chatterjee A, Biswas J, Chatterjee A, Bhattacharya S, Mukhopadhyay B, Mandal S. Psorinum therapy in treating stomach, gall bladder, pancreatic, and liver cancers: a prospective clinical study.  Evid Based Complement Alternat Med. 2011;2011:724743. http://www.hindawi.com/journals/ecam/2011/724743.html